• Explore /
  • Poster
  • / Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

Abstract Poster

Authors

Ghassan Abou-Alfa

Ghassan K. Abou-Alfa

Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Ghassan K. Abou-Alfa , Ann-Lii Cheng , Tim Meyer , Anthony B. El-Khoueiry , Masafumi Ikeda , Hoo Geun Chun , Sandrine J. Faivre , Junji Furuse , Jennifer J. Knox , Takuji Okusaka , Jerry Ping , Anne E. Borgman-Hagey , Robin Kate Kelley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01908426

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4150)

DOI

10.1200/jco.2014.32.15_suppl.tps4150

Abstract #

TPS4150

Poster Bd #

234A

Abstract Disclosures

Similar Posters

First Author: Ghassan K. Abou-Alfa

First Author: Robin Kate Kelley

First Author: Robin Kate Kelley

First Author: Robin Kate Kelley